Stoke Therapeutics (STOK) Net Cash Flow Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.62 Bn | 468.83 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.20 Bn | 115.95 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.57 Bn | 51.38 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 53.46% |
| 10 | Stoke Therapeutics | 1.89 Bn | 1.54 Bn | - | -49.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.30% |
| Dec 31, 2025 | 103.79% |
| Sep 30, 2025 | 58.23% |
| Jun 30, 2025 | -1,263.78% |
| Mar 31, 2025 | 1,241.69% |
| Dec 31, 2024 | -1,588.46% |
| Sep 30, 2024 | -1,986.41% |
| Jun 30, 2024 | 765.49% |
| Mar 31, 2024 | -116.75% |
| Dec 31, 2023 | 815.63% |
| Sep 30, 2023 | -104.56% |
| Jun 30, 2023 | 110.52% |
| Mar 31, 2023 | 226.32% |
| Dec 31, 2022 | 103.73% |
| Sep 30, 2022 | 333.61% |
| Jun 30, 2022 | 83.38% |
| Mar 31, 2022 | -207.08% |
| Dec 31, 2021 | -104.48% |
| Sep 30, 2021 | -86.63% |
| Jun 30, 2021 | -951.80% |